Chemours Company (The) (CC) Given Average Rating of “Buy” by Analysts

Chemours Company (The) (NYSE:CC) has received a consensus recommendation of “Buy” from the ten ratings firms that are currently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $55.67.

Several brokerages have recently issued reports on CC. UBS AG restated a “sell” rating and issued a $36.00 price objective (up previously from $35.00) on shares of Chemours Company (The) in a research note on Wednesday, June 14th. BidaskClub downgraded shares of Chemours Company (The) from a “buy” rating to a “hold” rating in a research note on Friday, August 11th. Zacks Investment Research downgraded shares of Chemours Company (The) from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 12th. Argus restated a “buy” rating and issued a $55.00 price objective (up previously from $50.00) on shares of Chemours Company (The) in a research note on Thursday, August 10th. Finally, Jefferies Group LLC raised their target price on Chemours Company (The) to $60.00 and gave the stock a “buy” rating in a research report on Thursday, August 3rd.

TRADEMARK VIOLATION WARNING: This piece was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be accessed at https://ledgergazette.com/2017/09/17/chemours-company-the-cc-given-average-rating-of-buy-by-analysts.html.

Chemours Company (NYSE:CC) traded up 1.41% during mid-day trading on Friday, reaching $50.36. 3,017,772 shares of the company traded hands. The company has a market capitalization of $9.31 billion, a P/E ratio of 32.96 and a beta of 3.64. The stock has a 50 day moving average price of $49.94 and a 200-day moving average price of $42.84. Chemours Company has a 52-week low of $14.07 and a 52-week high of $51.59.

Chemours Company (The) (NYSE:CC) last announced its quarterly earnings data on Wednesday, August 2nd. The specialty chemicals company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.85 by $0.02. The business had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.49 billion. Chemours Company (The) had a net margin of 4.96% and a return on equity of 122.97%. Chemours Company (The)’s quarterly revenue was up 14.8% on a year-over-year basis. During the same quarter last year, the company posted $0.27 earnings per share. Analysts expect that Chemours Company will post $3.51 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Friday, September 15th. Investors of record on Thursday, August 17th were given a $0.03 dividend. The ex-dividend date was Tuesday, August 15th. This represents a $0.12 annualized dividend and a yield of 0.24%. Chemours Company (The)’s dividend payout ratio (DPR) is currently 8.11%.

In related news, VP Amy Trojanowski sold 2,500 shares of the firm’s stock in a transaction on Friday, August 11th. The stock was sold at an average price of $46.03, for a total value of $115,075.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider E Bryan Snell sold 10,000 shares of the firm’s stock in a transaction on Friday, August 11th. The stock was sold at an average price of $46.24, for a total value of $462,400.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 38,837 shares of company stock valued at $1,865,603. 1.14% of the stock is owned by company insiders.

Hedge funds have recently modified their holdings of the stock. Financial Architects Inc lifted its position in Chemours Company (The) by 1,230.3% in the second quarter. Financial Architects Inc now owns 2,940 shares of the specialty chemicals company’s stock worth $111,000 after purchasing an additional 2,719 shares during the period. Acrospire Investment Management LLC lifted its holdings in shares of Chemours Company (The) by 3.4% during the second quarter. Acrospire Investment Management LLC now owns 3,076 shares of the specialty chemicals company’s stock valued at $117,000 after acquiring an additional 100 shares during the period. Benjamin F. Edwards & Company Inc. lifted its holdings in shares of Chemours Company (The) by 2,138.8% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 3,112 shares of the specialty chemicals company’s stock valued at $118,000 after acquiring an additional 2,973 shares during the period. Schroder Investment Management Group bought a new position in shares of Chemours Company (The) during the first quarter valued at $156,000. Finally, Smithfield Trust Co. lifted its holdings in shares of Chemours Company (The) by 521.4% during the second quarter. Smithfield Trust Co. now owns 4,791 shares of the specialty chemicals company’s stock valued at $182,000 after acquiring an additional 4,020 shares during the period. 72.90% of the stock is owned by hedge funds and other institutional investors.

Chemours Company (The) Company Profile

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

Analyst Recommendations for Chemours Company (The) (NYSE:CC)

Receive News & Ratings for Chemours Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours Company (The) and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply